|
|
|
LifeScienceHistory.com - Check us out on Instagram
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Agios Pharmaceuticals, Inc.
| | | Phone: | (617) 649-8600 | Year Established: | 2008 | Ticker: | AGIO | Exchange: | NASDAQ | Main Contact: | Steve Hoerter, CCO | | Other Contacts: | David Schenkein, M.D., Executive Chairman Scott Biller, Ph.D., CSO Chris Bowden, M.D., CMO Andrew Hirsch, CFO Min Wang, J.D., Ph.D., General Counsel Jacqualyn (“Jackie”) Fouse, Ph.D., CEO
| | Company Description | Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. | |
|
|
|
|
|